
Oncology NEWS International
- Oncology NEWS International Vol 17 No 5
- Volume 17
- Issue 5
Immunotherapy agent promising in NSCLC
GENEVA-Patients with NSCLC who received MAGE-A3 ASCI (antigen-specific cancer immunotherapeutic) had longer disease-free (HR 0.76) and overall survival (HR 0.81) than those who received placebo, although in this phase II study of 182 patients, the difference did not reach significance.
GENEVA-Patients with NSCLC who received MAGE-A3 ASCI (antigen-specific cancer immunotherapeutic) had longer disease-free (HR 0.76) and overall survival (HR 0.81) than those who received placebo, although in this phase II study of 182 patients, the difference did not reach significance. Johan Vansteenkiste, MD, PhD, of University Hospital Gasthuisberg, Belgium, reported the results, with 44 months of follow-up, at the 1st European Lung Cancer Conference (abstract 1480). An efficacy phase III study (MAGRIT) is ongoing.
Articles in this issue
about 18 years ago
NCCN greenlights nilotinib for imatinib-resistant CML patientsabout 18 years ago
No overall survival benefit for dose-intense regimen in SCLCabout 18 years ago
Make a note of new smoking cessation codesabout 18 years ago
Relistor for treating OICabout 18 years ago
Experts argue against need for phase III proton Rx trialsabout 18 years ago
Spotlight on Cancer Centersabout 18 years ago
Novel peptide vaccine promising in myeloid leukemiaabout 18 years ago
Intensive imatinib/chemo ups EFS in pediatric Ph+ ALLabout 18 years ago
Relapsing DLBCL patients respond to rituximab-based RxNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Related Content



















































